Over the past decades, numerous epidemiologic studies have shown an association of cardiovascular disease (CVD) with particulate air pollution exposures ([@b12-ehp-118-1406]; [@b22-ehp-118-1406]). Possible biologic pathways for this association include alterations in cardiac autonomic function, the release of circulating prooxidative and proinflammatory mediators from the lungs into the systemic circulation after particle inhalation, and translocation of ultrafine particles and soluble constituents of particles into the systemic circulation ([@b3-ehp-118-1406]). The pathway by which exposure to particulate pollutants adversely affects the cardiac autonomic nervous system may, in part, account for an increased risk of arrhythmias and sudden cardiac death associated with particulate exposure. In recent experimental studies, scientists prevented particle-induced cardiac oxidative stress by pretreating rats with autonomic nerve receptor antagonists ([@b25-ehp-118-1406]) and particle-induced neuroplasticity of cardiac vagal neurons ([@b20-ehp-118-1406]). The results of these studies have suggested that cardiac particle toxicity is mediated by autonomic nervous system stimulation.

Numerous epidemiologic studies have shown an association between particulate air pollution and cardiac autonomic dysfunction, as measured by heart rate variability (HRV) ([@b5-ehp-118-1406]; [@b10-ehp-118-1406]; [@b13-ehp-118-1406]; [@b19-ehp-118-1406]; [@b35-ehp-118-1406]). However, most previous studies have used a small number of subjects; only a few studies have been conducted in population-based cohorts ([@b13-ehp-118-1406]; [@b19-ehp-118-1406]; [@b35-ehp-118-1406]). Only one study ([@b19-ehp-118-1406]) examined an association with particulate matter (PM) ≤ 2.5 μm in aerodynamic diameter (PM~2.5~). [@b6-ehp-118-1406] have suggested that PM~2.5~ is more harmful to health than are larger particles \[which are included in measurements of PM ≤ 10 μm in aerodynamic diameter (PM~10~)\] because PM~2.5~ can penetrate deeper into the lung than PM~10~.

Some studies have found that associations between PM exposure and autonomic dysfunction are stronger among persons with type 2 diabetes ([@b19-ehp-118-1406]; [@b35-ehp-118-1406]), hypertension ([@b10-ehp-118-1406]; [@b19-ehp-118-1406]), and obesity ([@b4-ehp-118-1406]; [@b28-ehp-118-1406]). The findings from these studies indicate that preexisting cardiometabolic diseases may confer susceptibility to cardiac autonomic dysfunction by particle exposure. Metabolic syndrome (MetS), a cluster of health risks characterized by abdominal obesity, type 2 diabetes, hypertension, and dyslipidemia ([@b16-ehp-118-1406]), has been associated with increased activity of the sympathetic nervous system, as have the individual conditions that define MetS ([@b32-ehp-118-1406]). In a recent study from Korea, [@b15-ehp-118-1406] observed a significant reduction in HRV related to exposure to carbon monoxide (CO) among persons with MetS but not among persons without MetS ([@b15-ehp-118-1406]). Because of the increasing prevalence of MetS and its association with an increased risk of CVD, it is important to determine whether MetS or its individual components may increase susceptibility to the cardiovascular effects of air pollution.

We used data from the Multi-Ethnic Study of Atherosclerosis (MESA), a large population-based study, to investigate associations between HRV and PM~2.5~ and to assess potential effect modification by MetS and its components.

Materials and Methods
=====================

Study population
----------------

The MESA is a longitudinal study supported by the National Heart, Lung, and Blood Institute; its aim is to identify risk factors for subclinical atherosclerosis. A total of 6,814 participants 45--84 years old who were free of clinically apparent CVD at the baseline examination were recruited from six U.S. communities: Baltimore City and Baltimore County, Maryland; Chicago, Illinois; Forsyth County, North Carolina; Los Angeles County, California; northern Manhattan and the Bronx, New York; and St. Paul, Minnesota. Details of the study design are described elsewhere ([@b2-ehp-118-1406]). Our study used data from the baseline visit that occurred between July 2000 and August 2002. Of the 6,814 participants who completed the baseline clinical examination, a total of 1,349 were excluded from the study because of nonparticipation in the air pollution study (*n* = 618), missing or poor quality electrocardiogram (ECG) data (*n* = 401), missing information on PM~2.5~ exposure (*n* = 160), missing information on both ECG and PM~2.5~ (*n* = 65), or missing information on temperature (*n* = 11) and other covariates (*n* = 94). Therefore, 5,465 participants with complete data were available for the analyses. Compared with other participants, those who were excluded (*n* = 1,349) were older (65 years old vs. 62 years old), more likely to be African American (33% vs. 27%) and current smokers (16% vs. 12%), more likely to be from Baltimore (21% vs. 15%) and less likely to be from Chicago (13% vs. 18%), and at higher risk of hypertension (22% vs. 18%) and type 2 diabetes (25% vs. 19%). The study protocol was approved by the institutional review board at each study site, and written informed consent was obtained from each participant.

Air pollution and meteorologic data
-----------------------------------

Air pollutant data were extracted from the U.S. Environmental Protection Agency (EPA) Aerometric Information Retrieval System ([@b34-ehp-118-1406]). PM~2.5~ concentrations were obtained from 24-hr integrated samplers, which collected data daily or every third day. For each participant, we obtained PM~2.5~ concentration data for the 60 days before the day on which HRV measures were obtained. Each daily exposure measure was obtained from the monitor nearest to the participant's residence with available data for a given day. We constructed five exposure measures: PM~2.5~ concentration the day before HRV measurement, and average PM~2.5~ concentrations over the 2, 7, 30, and 60 days prior to HRV measurement. Gaseous pollutants \[sulfur dioxide (SO~2~), nitrogen dioxide (NO~2~), and CO\] were also included. Ozone was not analyzed because of incomplete information in the winter. Meteorologic data including temperature and dew point temperature were obtained from the National Climatic Data Center ([@b17-ehp-118-1406]). To control for weather, we used apparent temperature, defined as a person's perceived air temperature, which combines the effects of heat and humidity in one variable ([@b18-ehp-118-1406]).

HRV measurement
---------------

After at least a 5-min rest, three consecutive 10-sec recordings of simultaneous 12-lead ECGs (Marquette MAC-1200; GE Healthcare, Milwaukee, WI, USA) were measured and read electronically after transmission over analog phone lines to a central ECG reading center that was blinded to all clinical and personal details of the participants. Most (92%) of the ECGs were assessed in the morning. ECG abnormalities were identified by a program using Nova code criteria ([@b24-ehp-118-1406]) and Minnesota code criteria ([@b21-ehp-118-1406]). On ECGs with \> 50% normal-to-normal (NN) interbeat intervals, two ECG measures of HRV were calculated using three consecutive 10-sec recordings: the standard deviation of NN intervals (SDNN) and the root mean square of successive differences of NN intervals (rMSSD). In general, SDNN and rMSSD measures based on ultrashort (e.g., 10 sec) recordings indicate short-term, resting parasympathetic (respiratory) variation. We excluded participants who had only one 10-sec HRV measure (1%); averages of two (7%) or three (92%) 10-sec HRV measures were computed and included in the statistical analysis. The validity of the HRV calculation method was verified by senior electrocardiographers and a biostatistician using a test data set of 264 ECGs. Prior work has shown high correlations between 10-sec and 6-min measures: correlation coefficients \[95% confidence intervals (CIs)\] 0.76 (0.68--0.82) for SDNN and 0.82 (0.75--0.86) for rMSSD ([@b27-ehp-118-1406]).

MetS and individual metabolic abnormalities
-------------------------------------------

We used the criteria of the National Cholesterol Education Program Adult Treatment Panel III ([@b16-ehp-118-1406]) and defined persons with three or more of the following criteria as having MetS: *a*) abdominal obesity (waist circumference \> 102 cm in men or \> 88 cm in women); *b*) hypertriglyceridemia (≥ 150 mg/dL); *c*) low high-density lipoprotein (HDL) cholesterol (\< 40 mg/dL in men or \< 50 mg/dL in women); *d*) high blood pressure (≥ 130/85 mm Hg or use of antihypertensive medication); and *e*) impaired fasting glucose (≥ 110 mg/dL, or self-reported diabetes or use of diabetes medication). We used clinical cutoff points for each of the individual components of MetS rather than the criteria used in MetS above to maintain a high degree of specificity for each disease. Diabetes was defined as fasting blood glucose of ≥ 126 mg/dL and/or use of diabetes medication (insulin or oral hypoglycemic agents). Hypertension was defined as blood pressure ≥ 140/90 mm Hg or use of hypertension medication. Dyslipidemia was defined as having both hypertriglyceridemia and low HDL cholesterol.

Statistical analysis
--------------------

Linear regression analyses were used to test for the associations between HRV measures and PM~2.5~. HRV measures were log transformed to normalize and to stabilize the variance. The following potential confounding variables were selected *a priori* and included in the model regardless of statistical significance: age, sex, race/ethnicity, cigarette smoking, body mass index (BMI), fasting blood glucose, mean arterial pressure, use of cardiac medications (beta blockers, angiotensin-converting enzyme inhibitors, and calcium channel blockers), and the lagged moving average of apparent temperature corresponding to the same moving average period for PM~2.5~. Categorical variables were modeled as shown in [Table 1](#t1-ehp-118-1406){ref-type="table"}. We used beta blockers, angiotensin-converting enzyme inhibitors and calcium channel blockers as classes of antihypertensive medications to make our models comparable with the models used in [@b19-ehp-118-1406]. The results did not change when we used an indicator variable for all possible antihypertensive medications, including diuretics and angiotensin II receptor antagonists. We also considered education, alcohol consumption, physical activity, serum total cholesterol, serum triglyceride, and use of statins in our models, but only serum triglyceride was included in final models, as it was the only one that changed the beta coefficients of PM~2.5~ by \> 10%. To account for the nonlinear association of apparent temperature with HRV, we used a regression spline with 3 degrees of freedom (df). Season may be an important confounder, because both PM~2.5~ concentrations and HRV show seasonal variations. In MESA, seasons vary by study sites; for example, winter in Los Angeles is different from winter in Chicago or New York. To control for seasonality at different study sites, we added interaction terms between splines of apparent temperature (3 df) and study sites. This model captures site-specific seasonality. We also created an indicator variable of warm months by study sites. Warm months were defined as those in which the average monthly temperature was greater \> 10°C (50°F). For Baltimore, Forsyth County, and New York, warm months occurred from April to October. For Chicago and St. Paul, they occurred from May to October. Los Angeles has warm months all year long. We added this indicator variable to the model to remove any residual confounding by season. We also examined possible confounding effects of gaseous pollutants (SO~2~, NO~2~, and CO) and their independent associations with HRV.

We checked for possible nonlinear relations between HRV and other continuous covariates using penalized splines, but there was no evidence of strong nonlinear relations; thus, we fit all other continuous covariates as linear terms. We present effect estimates as percent change for an interquartile range (IQR) increase for PM~2.5~. We checked whether the relation between PM~2.5~ and HRV was linear by fitting PM~2.5~ as a smoothing term using penalized splines. This smoothing method makes no assumptions regarding the shape of the association ([@b36-ehp-118-1406]), and the penalized splines can be estimated in a generalized additive model using R (version 2.9.2; The R Foundation for Statistical Computing, Boston, MA).

Study site may be an important confounder or an effect modifier, because the composition of PM~2.5~ may vary by different locations. Two analytical approaches were used to account for site: one was to additionally adjust for study site in the regression model as described above, and the other was to construct site-specific regression models and pool the estimates using meta-analysis. Heterogeneity of effect estimates was assessed with a χ^2^ test with 5 df. If heterogeneity by study sites was found, random-effect models were used to obtain a pooled estimate while accounting for site heterogeneity.

To assess effect modification by MetS and its individual components, multiplicative interaction terms along with the main effects were included in regression models. We also examined effect modification by other individual-level factors, including sex, education, cigarette smoking, cardiac medication, and use of statins. The *p*-value of significance was \< 0.05.

Results
=======

[Table 1](#t1-ehp-118-1406){ref-type="table"} shows the distribution of demographic and clinical characteristics of the study participants. The average age of participants was 62 years, and approximately half of the participants were female. The prevalence of hypertension, type 2 diabetes, abdominal obesity, dyslipidemia, and MetS was 43%, 12%, 54%, 19%, and 32%, respectively. Persons with MetS were older, more likely to be women, and to have had lower HRV measures. Two days before the HRV measurement, PM~2.5~ concentrations averaged from 10.3 μg/m^3^ in St. Paul to 19.3 μg/m^3^ in Los Angeles, with an overall mean of 14.3 μg/m^3^. Overall, the correlations between PM~2.5~ and the corresponding moving averages of apparent temperature were modest (Spearman correlation coefficients between 0.21 and 0.31). Month averages of PM~2.5~ concentrations (30-day and 60-day means for PM~2.5~) were moderately correlated with shorter-term averages (prior day and 2-day mean PM~2.5~) (Spearman correlation coefficients 0.35 to 0.48).

[Table 2](#t2-ehp-118-1406){ref-type="table"} shows adjusted geometric means and geometric standard errors of HRV measures for sex, race/ethnicity, and study sites, stratified by MetS. In general, persons with MetS had lower HRV values than those without MetS. Women and African Americans had higher HRV measures than men and other race/ethnic groups, respectively. HRV measures differed by the study sites. For persons without MetS, HRV measures were lower in Baltimore and Chicago and higher in Forsyth County, Los Angeles, and St. Paul. For persons with MetS, Baltimore and Forsyth County had higher values, whereas Los Angeles had the lowest values. The differences in HRV values between persons with and without MetS were greatest in Los Angeles, and no differences in MetS status were observed among participants in Baltimore.

[Table 3](#t3-ehp-118-1406){ref-type="table"} presents adjusted associations of HRV measures with various lags of PM~2.5~. All PM~2.5~ lags showed inverse associations with HRV measures, and the associations were generally strongest for the 2-day moving average, especially for SDNN. Model 1 included age, sex, race/ethnicity, smoking status, BMI, fasting blood glucose, mean arterial pressure, serum triglyceride, cardiac medications, indicator of warm months, and regression splines of apparent temperature (3 df) as covariates. Model 2 added interaction terms between study sites and regression splines of apparent temperature along with main terms for sites and apparent temperature. This additional adjustment for site-specific apparent temperature made the associations slightly stronger for shorter moving averages of PM~2.5~ (1-day previous and 2-day and 7-day averages), whereas the associations with longer moving averages (30-day and 60-day averages) became weaker after such an adjustment. In Model 2, one IQR increment in 2-day average of PM~2.5~ (10.2 μg/m^3^) was associated with decreases of 1.84% (95% CI, −3.73 to 0.08) and 2.10% (95% CI, 0.0 to 4.17) in SDNN and rMSSD, respectively. Associations became stronger after adjustment for gaseous copollutants in all lag models (Model 3), with more pronounced changes noted when NO~2~ or CO were added to models (data not shown). There were no significant associations of HRV with gaseous pollutants (data not shown).

We conducted regression analyses for the 2-day moving average stratified by study site and controlled for covariates used in Model 1 to check heterogeneity of site-specific associations. No significant heterogeneity of site-specific associations was found (*p*-values for heterogeneity = 0.27 for SDNN and 0.11 for rMSSD). Overall associations from the meta-analysis were −1.83% (95% CI, −3.71 to 0.08) for SDNN and −2.03% (95% CI, −4.08 to 0.07) for rMSSD (data not shown).

[Figure 1](#f1-ehp-118-1406){ref-type="fig"} shows results for effect modification by MetS and its individual components in association between HRV and 2-day average of PM~2.5~. We found statistically significant effect modification by MetS. One IQR increase in 2-day PM~2.5~ was significantly associated with 5.16% (95% CI, 2.13--8.10) and 6.16% (95% CI, 2.85--9.35) decreases in SDNN and rMSSD, respectively, among persons with MetS, whereas no relationship was found among persons without MetS (*p*-values for interaction = 0.011 for SDNN and 0.005 for rMSSD). We also found significant associations of PM~2.5~ and rMSSD among persons with abdominal obesity, diabetes, or hypertension, but no significant associations were observed among persons without those conditions. The interaction terms between PM~2.5~ and each individual component of MetS in each model were not statistically significant. We also examined effect modification by sex, education, cigarette smoking, cardiac medication (beta blockers, angiotensin-converting enzyme inhibitors, and calcium channel blockers), and statin use, but no significant effect modification was observed (data not shown).

Discussion
==========

This cross-sectional, multiethnic, multicity study showed that exposure to greater levels of fine particles averaged for 2 days before the HRV measurement was associated with less HRV, as indicated by lower short-term recorded SDNN and rMSSD, markers of resting parasympathetic (vagal) variation of the heart. Individuals with MetS had significantly larger decreases in HRV measures in relation to PM~2.5~ than did those without MetS. The associations were also consistently stronger among persons with individual components of MetS (such as abdominal obesity, diabetes, hypertension, or dyslipidemia) than among persons without the components, although the differences were not statistically significant. These findings suggest that possible cardiovascular effects of PM~2.5~ may be mediated, in part, through altered autonomic function, particularly among persons with MetS. The observed associations did not differ by sex, race/ethnicity, study site, educational attainment, smoking status, and use of antihypertension and anticholesterol medications. These results were independent of individual-level confounders as well as other environmental factors.

Our findings are consistent with the results from a previous community-based study of HRV and PM~2.5~, but the magnitude of the associations in our study is smaller. A study conducted with 497 elderly men from the Normative Aging Study (NAS) found that the association of HRV was strongest with the 2-day (48-hr) average of PM~2.5~ ([@b19-ehp-118-1406]). In the present study, we modeled the same covariates used in the NAS to facilitate comparisons between the studies. In the NAS population, 8 μg/m^3^ of PM~2.5~ was associated with a 5.4% (95% CI, −1.5 to 11.8) decrease in SDNN, which is approximately three times larger than the magnitude of the association in our study. NAS participants with hypertension or diabetes were also more susceptible to PM~2.5~ exposure than were the participants without these conditions. Other population-based studies have examined PM~10~ rather than PM~2.5~. Liao and colleagues examined 4,899 middle-aged and elderly participants from the Atherosclerosis Risk in Communities Study and found that 11.5 μg/m^3^ of PM~10~ measured 1-day before was associated with a 1.03-msec (SE = 0.31) reduction in SDNN, which is equivalent to a 2.75% (95% CI, 1.13--4.37) decrease (based on the population mean of SDNN = 37.5 msec) ([@b13-ehp-118-1406]). They also found a stronger association among persons with hypertension.

Our study supports previous evidence that preexisting cardiometabolic diseases may confer susceptibility to particle-induced autonomic dysfunction. Furthermore, only MetS was identified as a significant modifying factor, and interactions between PM~2.5~ and its individual components did not reach statistical significance. This suggests that a clustering of cardiometabolic risk factors increases susceptibility to the adverse effects of particle exposure. MetS has been associated with diminished HRV among middle-aged and elderly persons ([@b9-ehp-118-1406]; [@b14-ehp-118-1406]; [@b30-ehp-118-1406]) and even young adults ([@b11-ehp-118-1406]). Persons with MetS are characterized by central fat accumulation, insulin resistance, glucose intolerance, and increased inflammation, which are associated with an overactivation of the sympathetic nervous system ([@b32-ehp-118-1406]). Sympathetic overactivity may have unfavorable impacts on the cardiovascular system such as development of hypertension, endothelial dysfunction, and heart failure ([@b33-ehp-118-1406]). It is unclear why and how MetS modifies the cardiovascular impact of particle exposure. We can speculate that particle exposure worsens the autonomic dysfunction caused by overactivation of the sympathetic nervous system because of MetS, but further toxicologic studies are needed to elucidate the biologic role of MetS in the association between particle exposure and autonomic function.

This study was conducted in six different cities in the United States with a uniform protocol including questionnaires, physical measurements, and analyses of laboratory and ECG measurements in centralized core laboratories. However, different cities have samples with different sociodemographic characteristics; they differ in meteorological conditions and also vary substantially in PM~2.5~ exposures. To account for this heterogeneity, we not only conducted regression analyses adjusting for study site and site-specific apparent temperature as smoothing terms, but we conducted meta-analysis using site-specific regression models. The observed associations were similar in analyses that adjusted for site as a covariate and in the meta-analysis approach.

The associations between PM~2.5~ and HRV measures became much stronger after adjustment for gaseous co-pollutants, especially NO~2~ and CO. Recent studies conducted in the United States suggest that ambient gaseous pollutant concentrations (such as CO and NO~2~) determined from central monitoring stations may not be good surrogates for corresponding individual-level gaseous exposures in epidemiologic research ([@b26-ehp-118-1406]; [@b29-ehp-118-1406]). Zeger and colleagues suggested that the effect estimate can be biased away from the true value if there is a strong negative correlation between measurement errors, because some of the effect of a more poorly measured variable may be transferred to the estimate of a better-measured variable ([@b37-ehp-118-1406]). Given that measurement errors for ambient gaseous pollutant are greater than those for ambient particles, adjustment for gaseous pollutants may lead to an overestimation of the true effect of particles.

Although statistically significant associations between PM~2.5~ and HRV measures were seen in this study, the magnitude of the associations was relatively small: approximately 2% decreases in SDNN and rMSSD with a 10.2-μg/m^3^ increase in 2-day average PM~2.5~ (Model 2, [Table 3](#t3-ehp-118-1406){ref-type="table"}). These decrements were roughly equivalent to a cross-sectional reduction in HRV associated with about 2 years of aging in our sample. Given the ubiquitous nature of particle exposure and the dose-dependent relation between reduced HRV and incidence of cardiovascular events, even those small effects, if causal, have the potential to influence public health.

An important strength of our study is that the analysis was based on a large community sample that included both sexes and various ethnic groups and cities, with a large number of participants. However, several limitations should be considered. MESA included a relatively healthy sample of persons without a prior history of CVD. If prior disease modifies the effects of PM on autonomic function, our results may not be generalizable to samples with preexisting cardiovascular conditions. However, the investigation of associations in large healthy samples is still of interest. The use of a healthy sample also minimizes residual confounding due to health conditions that could be related to HRV and to PM exposure, if persons with pre-existing conditions tend to live in or move to areas with greater PM exposure. Additionally, we restricted the analysis to participants with complete values for the variables included in the regression models. This approach may lead to bias if the missing values are not completely random ([@b23-ehp-118-1406]). Subjects included in the analysis were relatively healthier than those excluded, and there were small differences in exclusion rates by sites. Although we cannot categorically rule out selection bias, it is unlikely that subjects were systematically excluded based on outcome (i.e., HRV) and exposure data. MESA study sites use the same standardized protocols for quality control; hence, systematic differences in HRV measurement between sites or across subjects with different characteristics are unlikely. Although multiple imputation of missing data is an option, it requires a number of assumptions. Given the approach taken in prior MESA analyses (which have not used multiple imputation), we report results based on participants with complete data.

We assessed HRV using three consecutive 10-sec recordings. Generally, use of records at least 5 min in duration is recommended in accordance with the previous guidelines ([@b31-ehp-118-1406]). However, there has been interest in using ultrashort recordings, such as 10 sec in duration, from the standard 12-lead ECG, because these records are much easier to collect in clinical and epidemiologic settings ([@b7-ehp-118-1406]; [@b8-ehp-118-1406]). It has been suggested that repeatability of HRV measures from 10-sec recordings is high when the mean from two or three records is used, and correlations between the same measures from 10 sec and 6 min were quite high ([@b27-ehp-118-1406]). In our study, we recorded 10-sec ECGs three times and excluded participants with one 10-sec record. Because SDNN reflects overall variability of heart rate, which requires a fair amount of time to be computed (generally longer than 5 min), the physiologic meaning of SDNN (overall variability) measured for 10 sec may capture only part of SDNN derived from longer periods ([@b7-ehp-118-1406]). On the other hand, rMSSD reflects short-term variability seen with respiration at rest and is thought to be a marker of the parasympathetic nervous system variation ([@b31-ehp-118-1406]). Therefore, the 10-sec SDNN and rMSSD measures used in this study might reflect the same phenomenon, that is, parasympathetic modulation of the heart. The ultrashort records did not allow evaluation of frequency domain.

Another limitation is single measurement of HRV because of the cross-sectional design, which cannot rule out residual confounding by subject-specific characteristics. Previous studies from the NAS showed consistent findings in both cross-sectional ([@b19-ehp-118-1406]) and longitudinal designs ([@b1-ehp-118-1406]), and the magnitude of the associations did not change. Nevertheless, the future availability of repeated HRV measurements in this sample will allow analysis that relates within-person changes in HRV to within-person changes in exposures, thus tightly accounting for subject-specific confounders.

Like many other population-based air pollution studies, we did not measure person-level pollution exposure. We used PM~2.5~ exposure from the monitor nearest each participant's residence. This method is likely an improvement over using a single representative monitor located in the center of a city. In MESA, 38% of participants were not employed at the time of the survey (retired and not working, unemployed, or homemakers), and more than 75% reported spending 60% of their time either in their home or within 1 mile (1.6 km) of their home. This suggests that the exposure assignment based on participant's residence used in this study is reasonable. Nevertheless, we cannot exclude a possibility of exposure misclassification; however, such an error is likely to be nondifferential.

In summary, short-term exposure to PM~2.5~ was marginally significantly associated with cardiac autonomic dysfunction, as manifested by decreased HRV measures in a large, multicity, multi-ethnic, population-based sample. In addition, persons with MetS showed a larger reduction in HRV associated with PM exposures, suggesting MetS as a susceptibility factor to particle-induced autonomic dysfunction. Given the potential limitations, these results must be interpreted with caution. Our findings support the hypothesis that alterations in cardiac autonomic function may be one of the underlying mechanisms through which particulate air pollution increases the risk of CVD. The biologic role of MetS in enhancing susceptibility to particle toxicity remains to be determined.
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![Adjusted percent changes and 95% CIs in HRV measures for an IQR increase in PM~2.5~ (10.2 μg/m^3^) by MetS and its components (abdominal obesity, diabetes, hypertension, and dyslipidemia), MESA, 2000--2002. The adjusted covariates are the same as in Model 2, [Table 3](#t3-ehp-118-1406){ref-type="table"}, except for the covariates that are part of each effect modifier: The model for MetS did not include BMI, fasting glucose, mean arterial pressure (MAP), serum triglyceride, and cardiac medications (beta blockers, calcium channel blockers, ACE inhibitors); the model for abdominal obesity did not include BMI; the model for diabetes did not include fasting glucose; the model for hypertension did not include mean arterial pressure and cardiac medications; and the model for dyslipidemia did not include serum triglyceride.](ehp-118-1406f1){#f1-ehp-118-1406}
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Demographic and clinical characteristics of the study population with complete data, MESA 2000--2002.

                                                                                MetS                
  --------------------------------------------------------- ------------------- ------------------- -------------------
  Age (years)                                               62.2 ± 10.9         61.5 ± 10.2         63.5 ± 9.8
  Percent female                                            53.2                51.0                57.8
  Race/ethnicity (%)                                                                                
   African American                                         26.6                26.8                26.0
   Caucasian                                                38.9                40.4                35.8
   Chinese                                                  12.4                13.7                9.6
   Hispanic                                                 22.2                19.1                28.6
  Education (%)                                                                                     
   ≤ High school diploma                                    34.9                31.2                42.5
   Some college                                             28.8                28.1                30.2
   ≥ 4-year college                                         36.3                40.6                27.3
  Study site (%)                                                                                    
   Baltimore                                                14.7                14.7                14.8
   Chicago                                                  18.1                20.4                13.1
   Forsyth County                                           15.6                14.9                17.0
   Los Angeles                                              19.8                19.2                21.0
   New York                                                 16.1                16.6                15.0
   St. Paul                                                 15.8                14.2                19.1
  Smoking status (%)                                                                                
   Never                                                    51.0                51.1                50.9
   Former                                                   36.6                36.8                36.1
   Current                                                  12.4                12.1                13.0
  Hypertension (%)                                          43.4                32.3                66.8
  Diabetes (%)                                              11.8                3.8                 28.6
  Abdominal obesity (%)                                     53.7                38.6                85.2
  Dyslipidemia (%)                                          18.7                3.8                 49.8
  Use of hypertension medication (%)                        35.9                25.6                57.5
   Beta blockers (%)                                        8.5                 5.6                 14.4
   Ca^2+^ channel blockers (%)                              11.7                8.8                 17.7
   ACE inhibitors (%)                                       11.3                6.7                 20.8
  BMI (kg/m^2)^                                             28.3 ± 5.4          27.0 ± 4.9          31.1 ± 5.2
  Waist circumference (cm)                                  97.9 ± 14.2         94.0 ± 13.3         106.0 ± 12.5
  Fasting glucose (mg/dL)                                   96.5 ± 28.5         89.9 ± 17.6         110.4 ± 39.7
  Mean arterial pressure (mmHg)                             89.8 ± 12.3         88.2 ± 12.1         93.2 ± 12.1
  HDL (mg/dL)                                               51.0 ± 14.8         54.9 ± 14.9         42.8 ± 10.5
  Triglyceride (mg/dL)                                      131.9 ± 88.3        105.6 ± 58.2        186.8 ± 112.1
  Heart rate (beats/min)                                    63.0 ± 9.4          62.0 ± 9.0          65.1 ± 10.0
  HRV, GM (GSD)                                                                                     
   SDNN (msec)                                              18.8 (1.84)         19.5 (1.81)         17.4 (1.91)
   rMSSD (msec^2^)                                          20.9 (1.96)         21.7 (1.91)         19.4 (2.04)
  Environmental variables, \[prior 2 days, median (IQR)\]                                           
   PM~2.5~ (μg/m^3^)                                        14.3 (10.2--20.4)   14.4 (10.2--20.4)   14.0 (10.1--20.4)
   NO~2~ (ppb)                                              23.5 (15.8--31.5)   23.9 (16.5--31.9)   22.6 (15.3--30.9)
   SO~2~ (ppb)                                              3.6 (1.8--6.6)      3.7 (1.8--6.8)      3.3 (1.6--6.1)
   CO (ppm)                                                 0.90 (0.65--1.35)   0.90 (0.70--1.35)   0.90 (0.65--1.30)
   Apparent temperature (°C)                                11.5 (3.5--17.5)    11.3 (3.1--17.5)    11.6 (4.0--17.3)

Abbreviations: GM, geometric mean; GSD, geometric standard deviation. Unless otherwise noted, values are reported as mean ± SD.

###### 

Adjusted HRV for sex, race/ethnicity, and study sites by MetS, MESA, 2000--2002.

                      MetS                                                         
  ------------------- ------- -------------- -------------- ------- -------------- --------------
  Sex                                                                              
   Women              1,884   19.47 (1.01)   22.54 (1.02)   1,022   17.90 (1.02)   20.33 (1.02)
   Men                1,814   18.99 (1.01)   20.76 (1.02)   745     16.63 (1.03)   18.16 (1.03)
                                                                                   
  Race/ethnicity                                                                   
   African American   991     22.16 (1.02)   26.14 (1.02)   460     20.05 (1.03)   23.72 (1.04)
   Caucasian          1,494   19.32 (1.02)   20.28 (1.02)   632     17.10 (1.03)   18.04 (1.03)
   Chinese            505     17.19 (1.03)   19.56 (1.03)   170     15.87 (1.06    17.93 (1.06
   Hispanic           708     18.57 (1.02)   21.12 (1.03)   505     16.29 (1.03)   17.76 (1.04)
                                                                                   
  Study site                                                                       
   Baltimore          542     18.14 (1.03)   20.41 (1.03)   262     18.62 (1.05)   20.78 (1.05)
   Chicago            755     18.14 (1.02)   20.31 (1.02)   232     17.35 (1.04)   18.41 (1.05)
   Forsyth County     551     20.54 (1.03)   22.18 (1.03)   300     18.04 (1.04)   19.88 (1.05)
   Los Angeles        709     20.10 (1.02)   22.49 (1.02)   371     15.78 (1.04)   17.53 (1.04)
   New York           615     18.54 (1.02)   21.30 (1.03)   265     17.17 (1.04)   19.53 (1.05)
   St. Paul           526     20.08 (1.03)   23.28 (1.03)   337     16.72 (1.04)   19.33 (1.04)

Measures were log transformed for analysis and then exponentiated. Values are geometric means (geometric standard errors) adjusted for age and for the other two variables in the table.

###### 

Adjusted percent change (95% CI) in HRV measures for an IQR increase in PM~2.5~ in models with various lagged exposure measures, MESA 2000--2002.

                                               SDNN                     rMSSD                            
  -------------------------------------------- ------------------------ ------- ------------------------ ------
  1-day previous (IQR = 11.45 μg/m^3^)                                                                   
   Model 1                                     −1.18 (−2.92 to 0.59)    0.19    −1.67 (−3.57 to 0.26)    0.09
   Model 2                                     −1.49 (−3.35 to 0.40)    0.12    −1.82 (−3.85 to 0.25)    0.08
   Model 3                                     −1.67 (−3.77 to 0.47)    0.13    −2.02 (−4.32 to 0.32)    0.09
                                                                                                         
  2-day moving average (IQR = 10.20 μg/m^3^)                                                             
   Model 1                                     −1.57 (−3.32 to 0.20)    0.08    −1.99 (−3.89 to −0.05)   0.04
   Model 2                                     −1.84 (−3.73 to 0.08)    0.06    −2.10 (−4.17 to 0.00)    0.05
   Model 3                                     −2.25 (−4.38 to −0.08)   0.04    −2.61 (−4.93 to −0.23)   0.03
                                                                                                         
  7-day moving average (IQR = 7.66 μg/m^3^)                                                              
   Model 1                                     −0.53 (−2.32 to 1.29)    0.56    −1.04 (−2.99 to 0.95)    0.30
   Model 2                                     −0.74 (−2.80 to 1.36)    0.49    −1.19 (−3.43 to 1.11)    0.31
   Model 3                                     −0.83 (−3.17 to 1.57)    0.50    −1.49 (−4.04 to 1.12)    0.26
                                                                                                         
  30-day moving average (IQR = 6.18 μg/m^3^)                                                             
   Model 1                                     −1.10 (−3.19 to 1.05)    0.31    −2.14 (−4.41 to 0.19)    0.07
   Model 2                                     −0.69 (−3.57 to 2.28)    0.64    −1.77 (−4.90 to 1.46)    0.28
   Model 3                                     −1.90 (−5.28 to 1.61)    0.28    −3.72 (−7.36 to 0.07)    0.05
                                                                                                         
  60-day moving average (IQR = 5.32 μg/m^3^)                                                             
   Model 1                                     −0.87 (−3.04 to 1.36)    0.44    −1.79 (−4.16 to 0.64)    0.15
   Model 2                                     −0.25 (−3.56 to 3.18)    0.89    −1.09 (−4.70 to 2.65)    0.56
   Model 3                                     −1.81 (−5.80 to 2.35)    0.39    −3.74 (−8.03 to 0.76)    0.10

Model 1 adjusted for age, sex, race/ethnicity, smoking status, BMI, fasting glucose, mean arterial pressure, serum triglyceride, use of beta blockers, use of Ca^2+^ channel blockers, use of ACE inhibitors, season (warm vs. cold season), and regression splines (3 df) for moving averages of apparent temperature corresponding for the predictor. Model 2 includes Model 1 plus interactions between study sites and regression splines (3 df) for moving averages of apparent temperature corresponding for the predictor. Model 3 includes Model 2 plus gaseous copollutants (NO~2~, SO~2~, CO).
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